Physician profile
James P Smith
NPI 1962474973
$604.57
in general payments reported to CMS, 2019-2025
11 companies · $432 in 2025
The $432 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $15.98 · 2022: $18.43 · 2023: $13.32 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414 · Education: $30.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.47 |
| Education | $30.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $124.99 | 2019 | |
| United Therapeutics Corporation | $97.05 | 2025 | Tyvaso |
| Insmed, INC. | $79.34 | 2025 | Brinsupri, Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.48 | 2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $61.80 | 2020-2025 | Fasenra, Breztri |
| Glaxosmithkline, LLC. | $42.09 | 2025 | Trelegy Ellipta, Nucala |
| Merck Sharp & Dohme LLC | $39.92 | 2025 | Zerbaxa |
| Regeneron Healthcare Solutions, INC. | $31.59 | 2025 | Dupixent |
| Verona Pharma, INC. | $26.56 | 2025 | Ohtuvayre |
| Genzyme Corporation | $18.43 | 2022 | |
| Resmed Corp | $13.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.